drugset

drugset / Trial / NCT00944905

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT00944905 ↗

Phase 1 Completed 46 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.

Timeline

Start: 2009-07
Primary completion: 2012-11
Completion: 2012-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MDX-1203	Monoclonal antibody	—	Intravenous

Indications